P
Phathom Pharmaceuticals
Phathom Pharmaceuticals is a biopharmaceutical company
About Phathom Pharmaceuticals
Phathom Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing innovative treatments for acid-related gastrointestinal disorders. The company primarily serves adult patients suffering from conditions such as Erosive Esophagitis and heartburn. Operating in the healthcare and pharmaceutical market, Phathom Pharmaceuticals leverages its expertise to bring new therapeutic options to patients who need them most. The company's business model revolves around the research, development, and commercialization of prescription medicines, with its flagship product being VOQUEZNA (vonoprazan). This product is designed to heal acid-related damage to the esophagus and provide relief from heartburn. Phathom Pharmaceuticals generates revenue through the sale of its prescription medications, targeting healthcare providers and patients as its primary clients. The company is committed to ethical business practices and compliance with all applicable laws and regulations.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2018
- Headquarters
- Florham Park, United States
- Listing
- IPO 2019
- Employees
- 433
- Open positions
- 31
- Dealroom signal
- 75.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Aug 2024 | $130M | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | May 2023 | $131M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Phathom Pharmaceuticals is 7.4K monthly website visits, down 22.1% over the last three months. Phathom Pharmaceuticals's team grew 8.8% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 XeratausUsing a new approach toward design, development, and technologies to offer determined innovation for Healthcare Advancements |
Miami, United States | Operational | 1 | $50M | $100M |
 Clairvoyant TherapeuticsProvides evidence-based psychedelic therapy to help patients live healthier and enriched lives |
Vancouver, Canada | Acquired | |||
 OrchidGenetic testing solutions for personalized health risk assessment and family planning |
San Francisco, United States | Operational | |||
 SeriTechInnovative Health and Skin Care |
Barcelona, Spain | Operational | |||
 Mimosa TherapeuticsOffering research-grade natural psilocybin and drug potency test kits |
United States | Operational | |||
 CG OncologyFocused on developing bladder cancer therapeutics |
Irvine, United States | Operational | |||
 AntegenesGenetic tests for personalized cancer risk prevention |
Tartu, Estonia | Operational | |||
 GLX AnalytixBringing personalized medicine to your health care |
Copenhagen, Denmark | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Frazier Healthcare Partners
Series B and later3 investors entered at this stage
Hercules Capital
NovaQuest Capital Management
Sagard
Other known investors6 additional known investors
Abingworth
Catalys Pacific
Frazier Life Sciences
RA Capital Management
Sahsen Ventures
Takeda
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Phathom Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Phathom Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.